Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population.

Conway, Devon S; Hersh, Carrie M; Harris, Haleigh C; Hua, Le H

Conway, Devon S; Hersh, Carrie M; Harris, Haleigh C; Hua, Le H.

Afiliación

Conway DS; Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, USA.
Hersh CM; Lou Ruvo Center for Brain Health, Cleveland Clinic Foundation, USA.
Harris HC; Lou Ruvo Center for Brain Health, Cleveland Clinic Foundation, USA.
Hua LH; Lou Ruvo Center for Brain Health, Cleveland Clinic Foundation, USA.

Mult Scler J Exp Transl Clin ; 6(1): 2055217320902488, 2020.

Article en En | MEDLINE | ID: mdl-32064117

Palabras clave

Multiple sclerosis; disease-modifying therapies; natalizumab; outcome measurement; treatment response

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Mult Scler J Exp Transl Clin Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google